# 131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma

> **NCT00798148** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Tehran University of Medical Sciences** · enrollment: 10 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** 131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT00798148
- **Lead sponsor:** Tehran University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-09
- **Primary completion:** 2012-07
- **Final completion:** —
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2012-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00798148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00798148, "131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00798148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*